REGENXBIO Inc (RGNX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

9600 BLACKWELL ROAD ROCKVILLE, MD 20850

REGENXBIO Inc. operates as a biotechnology company. The Company focuses on the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. REGENXBIO serves customers worldwide.

Data based on most recent fiscal year report
Market Cap897.12 Million Shares Outstanding31.15 Million Avg Volume472.562 Thousand
1-Yr BETA vs S&P TR1.93 Current Ratio11.63 Quick Ratio11.63

Are you looking for this stock instead?

View SEC Filings from RGNX instead.

View recent insider trading info

Funds Holding RGNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RGNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

53.1 Thousand total shares from 5 transactions

Exercise Derivative Conversion (M)

33 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HAYDEN DONALD J JR

0 2020-01-14 2

BESHAR LUKE M

  • Director
168,000 2020-01-09 1

VASISTA VITTAL CHIEF FINANCIAL OFFICER

224,715 2020-01-08 5

SIMPSON CURRAN SVP, PRODUCT DEVELOPMENT & CTO

0 2020-01-02 5

MILLS KENNETH T. PRESIDENT AND CEO

0 2020-01-02 10

FMR LLC

  • 10% Owner
  • SEE REMARK 1
18,375,638 2020-01-02 0

CHRISTMAS PATRICK J. SVP, GENERAL COUNSEL

0 2020-01-02 5

DANOS OLIVIER CHIEF SCIENTIFIC OFFICER

0 2020-01-02 3

PAKOLA STEVE CHIEF MEDICAL OFFICER

0 2020-01-02 3

STUMP DAVID C

  • Director
0 2019-06-28 1

ABDUN-NABI DANIEL BOARD OF DIRECTORS

109,351 2019-06-25 1

SAMUELS CAMILLE D

  • Director
10,169 2019-06-20 0

FOX ALLAN M.

0 2019-05-31 1

KARABELAS ARGERIS N

0 2019-05-31 1

TASSE DANIEL

0 2019-05-31 1

GLUCKSMANN ALEXANDRA

0 2019-05-31 1

YOO STEPHEN CHIEF MEDICAL OFFICER

0 2018-12-03 0

ENGLEMAN EDGAR

  • Director
  • 10% Owner
No longer subject to file 2018-02-05 0

ALI FARAZ CHIEF BUSINESS OFFICER

  • Officer
0 2017-01-04 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT CO

DEERFIELD MGMT III, L.P.

DEERFIELD PRIVATE DESIGN FUND III, L.P.

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

DEERFIELD PARTNERS, LP

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2015-09-22 0

FLYNN JAMES E

DEERFIELD MGMT III, L.P.

DEERFIELD MANAGEMENT CO

DEERFIELD PRIVATE DESIGN FUND III, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
0 2015-09-16 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

HAYDEN DONALD J JR

2020-01-14 M 30,000 d 159,100 0.00 direct yes

HAYDEN DONALD J JR

2020-01-14 S 30,000 $45.60 d 0 0.00 direct yes

HAYDEN DONALD J JR

2020-01-14 M 30,000 $0.85 a 30,000 0.00 direct yes

VASISTA VITTAL CHIEF FINANCIAL OFFICER

2020-01-08 M 3,000 d 29,374 224,715.00 direct yes

VASISTA VITTAL CHIEF FINANCIAL OFFICER

2020-01-08 M 3,000 $13.09 a 232,215 224,715.00 direct yes

VASISTA VITTAL CHIEF FINANCIAL OFFICER

2020-01-08 S 5,100 $41.92 d 224,715 224,715.00 direct yes

VASISTA VITTAL CHIEF FINANCIAL OFFICER

2020-01-08 S 2,400 $41.40 d 229,815 224,715.00 direct yes

VASISTA VITTAL CHIEF FINANCIAL OFFICER

2020-01-02 A 50,000 a 50,000 0.00 direct

CHRISTMAS PATRICK J. SVP, GENERAL COUNSEL

2020-01-02 A 50,000 a 50,000 0.00 direct

DANOS OLIVIER CHIEF SCIENTIFIC OFFICER

2020-01-02 A 48,000 a 48,000 0.00 direct

PAKOLA STEVE CHIEF MEDICAL OFFICER

2020-01-02 A 42,600 a 42,600 0.00 direct

MILLS KENNETH T. PRESIDENT AND CEO

2020-01-02 A 270,000 a 270,000 0.00 direct

SIMPSON CURRAN SVP, PRODUCT DEVELOPMENT & CTO

2020-01-02 A 46,000 a 46,000 0.00 direct

SIMPSON CURRAN SVP, PRODUCT DEVELOPMENT & CTO

2019-12-09 S 9,399 $43.40 d 30,101 23,948.00 direct

SIMPSON CURRAN SVP, PRODUCT DEVELOPMENT & CTO

2019-12-09 S 6,153 $44.26 d 23,948 23,948.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments